Esperion Therapeutics Inc. NASDAQESPR said both doses of its ETC1002 met the primary endpoint compared to ezetimibe in a Phase IIb study to treat patients with hypercholesterolemia with or without statin intolerance. Ezetimibe which inhibits absorption of ...
↧